Baxter Ventures, Mayo Clinic, Velocity Pharma Create Vitesse Biologics

Baxter Ventures of Baxter International Inc. (BAX), together with the Mayo Clinic and Velocity Pharmaceutical Development, LLC Monday announced the formation of Vitesse Biologics, LLC, with a focus on early stage research and development, by leveraging expertise in various fields.

Vitesse will focus on the development of antibody and protein-based therapeutics in the areas of immunology, hematology, and oncology. Baxter is in the process of a spin off to Baxalta Inc. by mid 2015.

The collaboration will help advance promising therapies quickly through the development process. As per the agreement, Baxter BioScience will provide global commercialization, antibody and protein development and manufacturing capabilities; Mayo Clinic researchers will execute the Phase I clinical trials; VPD will be responsible for target identification, selection of early stage drug candidates and will lead the design and execution of pre-clinical and clinical protocols.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Activity in the U.S. manufacturing sector slowed by more than expected in the month of September but still saw continued growth, according to a report released by the Institute for Supply Management on Monday. Stocks have moved sharply higher in morning trading on Monday, regaining ground following a dismal September. The major averages have all shown substantial moves to the upside. Swedish geneticist Svante Paabo has won this year's Nobel Prize in Physiology/Medicine for his discoveries concerning the genomes of extinct hominins and human evolution. Through his pioneering research, Svante Pääbo accomplished something seemingly impossible: sequencing the genome of the Neanderthal, an extinct relative of present-day humans. He also made the sensational discovery of a previous
Follow RTT